{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:12:01Z","timestamp":1785564721634,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":1013,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Linea D1 Universit\u00e0 Cattolica, Facolt\u00e0 Medicina e Chirurgia, Roma"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1002\/rth2.12315","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T09:31:56Z","timestamp":1582882316000},"page":"413-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia"],"prefix":"10.1016","volume":"4","author":[{"given":"Monica","family":"Sacco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ranalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Lancellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Dragani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimondo","family":"De Cristofaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12315_bb0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jbior.2018.11.007","article-title":"Heterogeneity in myeloproliferative neoplasms: Causes and consequences","volume":"71","author":"O'Sullivan","year":"2019","journal-title":"Adv Biol Regul"},{"key":"10.1002\/rth2.12315_bb0015","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2013-06-508416","article-title":"Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis","volume":"122","author":"Silver","year":"2013","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0020","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0025","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0030","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ajh.23970","article-title":"Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO\u2010criteria and stratified by calendar period of diagnosis","volume":"90","author":"Barbui","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12315_bb0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"European Collaboration on Low\u2010dose Aspirin in Polycythemia Vera I. Efficacy and safety of low\u2010dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12315_bb0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population\u2010based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1002\/rth2.12315_bb0045","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","article-title":"Platelet activation and inhibition in polycythemia vera and essential thrombocythemia","volume":"121","author":"Patrono","year":"2013","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0050","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta\u2010analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/rth2.12315_bb0055","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population\u2010based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1002\/rth2.12315_bb0060","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood.V64.5.981.981","article-title":"Acquired von Willebrand's disease in the myeloproliferative syndrome","volume":"64","author":"Budde","year":"1984","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0065","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V82.6.1749.1749","article-title":"Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma","volume":"82","author":"Budde","year":"1993","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajh.2830260204","article-title":"Acquired von Willebrand disease in patients with polycythemia rubra vera","volume":"26","author":"Mohri","year":"1987","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12315_bb0075","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1055\/s-0038-1645964","article-title":"Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis","volume":"58","author":"Lopez\u2010Fernandez","year":"1987","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12315_bb0080","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ajh.2830490406","article-title":"Platelet von Willebrand factor abnormalities in myeloproliferative syndromes","volume":"49","author":"Castaman","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12315_bb0085","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jth.12967","article-title":"Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count","volume":"13","author":"Lancellotti","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12315_bb0090","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2009-08-236679","article-title":"The contribution of cyclooxygenase\u20101 and \u20102 to persistent thromboxane biosynthesis in aspirin\u2010treated essential thrombocythemia: implications for antiplatelet therapy","volume":"115","author":"Dragani","year":"2010","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0095","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ajh.20830","article-title":"Acquired von Willebrand syndrome: an update","volume":"82","author":"Franchini","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12315_bb0100","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.thromres.2015.07.029","article-title":"Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera \u2010 retrospective analysis of 142 consecutive cases","volume":"136","author":"Mital","year":"2015","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12315_bb0105","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMoa1208500","article-title":"Treatment target in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1002\/rth2.12315_bb0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/ijlh.12874","article-title":"Standardization and comparison of nonautomated assays to measure the collagen binding activity of von Willebrand factor","volume":"40","author":"Oliveira","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"10.1002\/rth2.12315_bb0115","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3324\/haematol.2011.042945","article-title":"ADAMTS13 activity and antigen during therapy and follow\u2010up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome","volume":"96","author":"Yang","year":"2011","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12315_bb0120","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd\u2010Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro\u2010thrombotic state due to increased P\u2010selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12315_bb0130","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617F\u2010positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms","volume":"111","author":"Etheridge","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/rth2.12315_bb0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-017-0425-z","article-title":"Driver mutations (JAK2V617F, MPLW515L\/K or CALR), pentraxin\u20103 and C\u2010reactive protein in essential thrombocythemia and polycythemia vera","volume":"10","author":"Lussana","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1002\/rth2.12315_bb0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2004-01-0107","article-title":"Effects of inflammatory cytokines on the release and cleavage of the endothelial cell\u2010derived ultralarge von Willebrand factor multimers under flow","volume":"104","author":"Bernardo","year":"2004","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0145","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2006-10-048298","article-title":"Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu\/BCAM","volume":"110","author":"Wautier","year":"2007","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0150","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2012-07-440487","article-title":"JAK2V617F activates Lu\/BCAM\u2010mediated red cell adhesion in polycythemia vera through an EpoR\u2010independent Rap1\/Akt pathway","volume":"121","author":"De Grandis","year":"2013","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0155","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII\u2010VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0160","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010589","article-title":"Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins","volume":"97","author":"Kato","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1002\/rth2.12315_bb0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12872-018-0762-z","article-title":"Association between brain\u2010derived neurotrophic factor and von Willebrand factor levels in patients with stable coronary artery disease","volume":"18","author":"Jin","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1002\/rth2.12315_bb0170","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/euhj.2001.3237","article-title":"von Willebrand factor and coronary heart disease: prospective study and meta\u2010analysis","volume":"23","author":"Whincup","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1002\/rth2.12315_bb0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0008-6363(97)00039-4","article-title":"von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?","volume":"34","author":"Lip","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1002\/rth2.12315_bb0180","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","article-title":"von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes","volume":"117","author":"Spiel","year":"2008","journal-title":"Circulation"},{"key":"10.1002\/rth2.12315_bb0185","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1538-7836.2006.01949.x","article-title":"von Willebrand factor, endothelial dysfunction, and cardiovascular disease","volume":"4","author":"Vischer","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12315_bb0190","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1161\/STROKEAHA.110.586289","article-title":"High von Willebrand factor levels increase the risk of stroke: the Rotterdam study","volume":"41","author":"Wieberdink","year":"2010","journal-title":"Stroke"},{"issue":"Suppl 1","key":"10.1002\/rth2.12315_bb0195","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.thromres.2007.03.011","article-title":"The role of von Willebrand factor in thrombus formation","volume":"120","author":"Ruggeri","year":"2007","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12315_bb0200","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0038-1650579","article-title":"Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation","volume":"76","author":"van Genderen","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12315_bb0205","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep\u2010vein thrombosis","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet"},{"key":"10.1002\/rth2.12315_bb0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor","volume":"17","author":"Rietveld","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12315_bb0215","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1160\/TH07-04-0279","article-title":"Von Willebrand factor: looking back and looking forward","volume":"98","author":"Ruggeri","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12315_bb0220","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/jth.13749","article-title":"Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice","volume":"15","author":"Swystun","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1002\/rth2.12315_bb0225","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/asheducation-2009.1.629","article-title":"Idiopathic erythrocytosis: a disappearing entity","volume":"2009","author":"McMullin","year":"2009","journal-title":"Hematology"},{"key":"10.1002\/rth2.12315_bb0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3233\/CH-170304","article-title":"Increased plasma viscosity in plasma cell dyscrasia and whole blood viscosity in polycythemia vera","volume":"70","author":"Shin","year":"2018","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1002\/rth2.12315_bb0235","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta\u2010analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv"},{"key":"10.1002\/rth2.12315_bb0240","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exphem.2017.02.001","article-title":"The calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera","volume":"50","author":"Falchi","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1002\/rth2.12315_bb0245","doi-asserted-by":"crossref","first-page":"8537","DOI":"10.1074\/jbc.273.14.8537","article-title":"Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin","volume":"273","author":"Pipe","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1002\/rth2.12315_bb0250","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1309\/W76QF806CE80CL2T","article-title":"Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis","volume":"124","author":"Favaloro","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1002\/rth2.12315_bb0255","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/rth2.12315_bb0260","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.2018834044","article-title":"How I treat polycythemia vera","volume":"134","author":"Spivak","year":"2019","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","article-title":"Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera","volume":"41","author":"Rottenstreich","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1002\/rth2.12315_bb0270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12315_bb0275","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12315_bb0280","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"Barbui","year":"2014","journal-title":"Blood"},{"key":"10.1002\/rth2.12315_bb0285","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frth2.12315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12315","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922019902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922019902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:19:21Z","timestamp":1762863561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922019902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S2475037922019902"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12315","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}